INCRETIN & RECEPTOR RESEARCH

MOTS-C and Mitochondrial Metabolic Pathway Research

Velox Peptides Research Team·Published May 2026·6 min read
Peptide Length
16 amino acids
Origin
Mitochondrial 12S rRNA
Key Pathway
AMPK signalling
HPLC Purity
≥99% (batch-verified)
For in vitro research use only. This summary of the preclinical literature is provided for scientific reference, not medical advice. MOTS-C is not for human or veterinary consumption.

What is MOTS-C?

MOTS-C (Mitochondrial Open reading frame of the Twelve S rRNA type-C) is a 16-amino-acid peptide encoded not in the cell nucleus but within the mitochondrial genome — specifically the 12S ribosomal RNA region. It belongs to a small, comparatively recently described class of mitochondrial-derived peptides (MDPs) that appear to act as signalling molecules between the mitochondria and the rest of the cell.

Because it is one of the first mitochondrial-derived peptides shown to have a defined metabolic signalling role, MOTS-C is of significant interest to researchers studying how mitochondria communicate metabolic status to the cell.

AMPK and metabolic signalling

AMPK activation. The most studied property of MOTS-C in preclinical models is its association with activation of AMP-activated protein kinase (AMPK) — a central cellular energy sensor that switches on when energy is low and promotes glucose uptake and fatty-acid oxidation. In rodent and cell-culture studies, MOTS-C is associated with increased AMPK activity and downstream effects on glucose metabolism.

Nuclear translocation under stress. Research has described MOTS-C moving to the cell nucleus under metabolic stress, where it is associated with the regulation of stress-response and antioxidant gene programmes — a mechanism that has made it a tool for studying mitochondrial-to-nuclear signalling.

Exercise and metabolic homeostasis. Animal-model studies have examined MOTS-C in the context of exercise capacity, insulin sensitivity and age-related metabolic decline, positioning it as a research probe for metabolic-homeostasis pathways.

Research context

MOTS-C sits in the incretin & receptor research category alongside other compounds studied for metabolic-pathway signalling. Researchers investigating cellular energy regulation may study it in parallel with NAD+ precursors and incretin-pathway peptides to compare distinct mechanisms of metabolic control.

Velox Peptides supply information

Velox Peptides supplies MOTS-C as a lyophilised powder at ≥99% HPLC-verified purity with a batch certificate of analysis available on request. For reconstitution, see the reconstitution calculator. Supplied strictly as a research reagent for in vitro use.

References & further reading

  1. Lee C et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism, 2015.
  2. Reynolds JC et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nature Communications, 2021.

Summaries are paraphrased from the peer-reviewed preclinical literature. For full source citations, email veloxpeps@gmail.com.

Frequently asked questions

What is MOTS-C?
MOTS-C is a 16-amino-acid mitochondrial-derived peptide encoded in the mitochondrial 12S rRNA region. It is studied as a metabolic signalling molecule and supplied by Velox Peptides for in vitro research use only.
What pathway is MOTS-C associated with?
In preclinical models MOTS-C is most associated with activation of AMPK, a central cellular energy sensor, and with mitochondrial-to-nuclear stress signalling.
What purity is Velox Peptides MOTS-C?
MOTS-C is HPLC-verified at a minimum of ≥99% purity, with batch documentation available on request.
Is MOTS-C legal to buy in the UK?
Yes — for in vitro research purposes. It is not a licensed medicine and not approved for human use. Velox Peptides supplies it solely as a research reagent.
Compliance statement. Velox Peptides supplies research reagents for in vitro use by qualified researchers. Every compound is sold strictly as a research reagent. No product is a medicinal product within the meaning of the Human Medicines Regulations 2012. No product has been evaluated by the MHRA or FDA. No product is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale. See our Research Use Policy and MHRA Statement.

All research summaries on this page are derived from publicly available peer-reviewed literature. Velox Peptides makes no therapeutic claims. For research use only.